Compare Novartis AG (NVS) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Prudential Financial Inc — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Prudential Financial Inc trades at $113.09 (market cap $39.17B). The key difference: Novartis AG is far larger — about 6.9× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Prudential Financial Inc for 145 Days on average.
| NVS | PRU | |
|---|---|---|
Market Cap | $268.57B | $39.17B |
Volume | 1,532,573 | 1,436,917 |
Sector | Health | Financials |
52-Week High | $168.62 | $125.13 |
52-Week Low | $121.80 | $92.00 |
Typical Hold Time | 82 Days | 145 Days |
Enterprise Value | $309.89B | $67.95B |
Dividend Yield | 3.31% | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Prudential Financial (PRU) trades at $113.09, up 0.65% with bearish technical signals but attractive valuation metrics including a P/E of 10.29 and P/S of 0.61. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company is executing a strategic overhaul including $3 billion capital rotation and $750 million cost savings while exiting emerging markets through the $185 million Alexforbes sale. Cash flow trends show strong operational performance with $6.3 billion from operations in 2025.
PRU presents a value opportunity with below-market valuations and dividend yield support, though technical weakness and mixed analyst sentiment warrant caution. The strategic refocus on core insurance and wealth management businesses positions the company for improved capital efficiency, while higher interest rates benefit investment income. Key risks include execution challenges in the restructuring and competitive pressures in the insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
